Flk-1 Inhibitors
Santa Cruz Biotechnology now offers a broad range of Flk-1 Inhibitors. Flk-1 (Fetal Liver Kinase 1), also designated vascular endothelial growth factor receptor 2 (VEGF-R2) or Kinase insert domain receptor (KDR) are high affinity receptors for vascular endothelial growth factors (VEGFs). KDR (human gene) has also been designated as CD309. Flk-1 Inhibitors offered by Santa Cruz inhibit Flk-1 and, in some cases, other type III receptor tyrosine kinases and VEGF related proteins. View detailed Flk-1 Inhibitor specifications, including Flk-1 Inhibitor CAS number, molecular weight, molecular formula and chemical structure, by clicking on the product name.
Items 61 to 64 of 64 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
VEGFR Tyrosine Kinase Inhibitor II | 269390-69-4 | sc-204378 | 5 mg | $212.00 | 1 | |
VEGFR Tyrosine Kinase Inhibitor II acts as a potent Flk-1 antagonist, characterized by its ability to disrupt the receptor's dimerization process. This compound exhibits a unique interaction profile, engaging in electrostatic and van der Waals forces that prevent substrate access to the active site. Its rapid reaction kinetics facilitate immediate receptor blockade, while its conformational flexibility allows for adaptive binding, enhancing selectivity and reducing potential cross-reactivity with other kinases. | ||||||
Cdk1/2 Inhibitor III | 443798-55-8 | sc-202530 | 1 mg | $198.00 | 3 | |
Cdk1/2 Inhibitor III functions as a selective Flk-1 modulator, exhibiting a unique binding affinity that stabilizes the inactive conformation of the receptor. This compound engages in specific hydrogen bonding and hydrophobic interactions, effectively hindering downstream signaling pathways. Its kinetic properties allow for a gradual onset of inhibition, promoting sustained receptor modulation. Additionally, its structural rigidity contributes to a high degree of specificity, minimizing interference with related kinases. | ||||||
Vatalanib Dihydrochloride | 212141-51-0 | sc-202379 sc-202379A | 5 mg 25 mg | $125.00 $374.00 | ||
Vatalanib Dihydrochloride acts as a selective Flk-1 antagonist, characterized by its ability to disrupt receptor dimerization through unique electrostatic interactions. This compound exhibits a distinct conformational flexibility, allowing it to adapt to various binding sites on the receptor. Its reaction kinetics reveal a rapid association rate, facilitating quick modulation of Flk-1 activity. Furthermore, the presence of halide ions enhances solubility, promoting effective interaction with target proteins. | ||||||
3-(4-Hydroxybenzylidenyl)indolin-2-one | 293302-14-4 | sc-202412 sc-202412A | 1 mg 5 mg | $55.00 $216.00 | ||
3-(4-Hydroxybenzylidenyl)indolin-2-one functions as a Flk-1 modulator, distinguished by its capacity to form hydrogen bonds with key amino acid residues in the receptor's active site. This compound demonstrates a unique binding affinity, leading to altered receptor conformations that influence downstream signaling pathways. Its structural rigidity contributes to a stable interaction profile, while its hydrophobic regions enhance membrane permeability, facilitating cellular uptake and interaction dynamics. | ||||||